| Date | Title | Description |
| 07.01.2026 | Eli Lilly set to back Aktis Oncology’s upsized $318M IPO | Please subscribe to IBJ to decode this article.
blsOiipL hei0nlIs ui-m zteieIepr k trillnc $0insitti 5anis t o.Eo lsfe eoe rf imi .lsea1glnrglnwynhlinb%,aaofrntcdo ydC fa.aea dic0id ycsdnr Aiioaof eotosgt bsisrinn l df eohn
e1mrihdnaieSqIPo... |
| 13.05.2025 | J&J, Eli Lilly join $85M financing for newly unveiled gene editing biotech Stylus | Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, co-founder Patrick Hsu, Ph.D., told Fierce Biotech.
“Stylus was founded in a post-platform era, where the market deman... |
| 28.01.2025 | Cancer Immunotherapy Market, Valued at $125.68 Billion in 2025, Sees $194.64 Billion Opportunity by 2029 - Dominated by Amgen, AstraZeneca, Roche, Bayer, and Eli Lilly | Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report 2025" has been added to ResearchAndMarkets.com's offering.
This Cancer Immunotherapy market report covers market characteristics, size & growth,... |
| 21.09.2021 | Eli Lilly and : Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of t... | INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results of its previously announced cash tender offer for specified series of its outstanding debt securities. Lilly also announ... |
| 06.07.2021 | Eli Lilly’s $15M investment deepens link to startup developing new class of RNA meds | Eli Lilly is making a small equity investment in a startup that recently became a research partner, deepening its connection to a company that could give the pharmaceutical giant a place in the growing field of RNA therapies.
The $15 millio... |
| 22.01.2021 | Lilly Makes $30M Limited Partner Investment in Unseen Capital Health Fund | Eli Lilly and Company (NYSE: LLY) made a $30m limited partner investment in Unseen Capital Health Fund LP, a newly-formed venture fund created by racially diverse and historically underrepresented business leaders.
The new fund is intended ... |
| 15.01.2021 | Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund | |
| 05.01.2021 | ELI LILLY AND COMPANY
Eli Lilly and : Lilly-Backed Terns Pharmaceuticals Raises $87 Million in Series C Round | By Colin Kellaher
Terns Pharmaceuticals Inc., a biopharmaceutical startup backed by Eli Lilly & Co., on Tuesday said it raised $87 million in a Series C funding round at an undisclosed valuation.
Terns said Deerfield Management Co. led ... |
| 05.01.2021 | Eli Lilly and : Lilly-Backed Terns Pharmaceuticals Raises $87 Million in Series C Round | By Colin Kellaher
Terns Pharmaceuticals Inc., a biopharmaceutical startup backed by Eli Lilly & Co., on Tuesday said it raised $87 million in a Series C funding round at an undisclosed valuation.
Terns said Deerfield Management Co. led ... |
| 17.12.2020 | Eli Lilly lands $1B deal in gene therapy space | Eli Lilly has agreed to purchase Prevail Therapeutics for total consideration of $26.50 per share, valuing the company at just over $1 billion. Based in New York, Prevail is a developer of gene therapies designed to target the root cause of... |
| 30.10.2017 | Atlas, Amgen, Lilly back Kymera’s $30M series A | Atlas-incubated Kymera Therapeutics has gotten off a $30 million series A and taken on Pierre Fabre’s R&D head as its new chief.
Sponsored by Agilent Technologies
How would you like to win free bench space at Lab Central for one scienti... |
| 24.03.2017 | Teacher’s pet Eli Lilly announces $850M investment in U.S. | According to Lilly President and CEO David Ricks, the company’s 140-year commitment to the U.S. market, combined with an expanding pipeline, drove the investment.
“Our future at Lilly is bright, as we’re on a path to launch 20 new products ... |
| 18.01.2017 | Term Sheet — Wednesday, January 18 | WITHER VR
The following is from the latest print edition of Fortune, where I write a regular column about technology and startups called “Boom With a View.”
Paid Content You can't secure what you can't see From ExtraHop
Still, the view from... |
| 18.01.2017 | Lilly drops $960M to acquire CoLucid and its late-stage migraine drug | CoLucid is built around lasmiditan, a migraine drug first discovered by Lilly and then out-licensed to CoLucid in 2005. To fuel its development, the Cambridge, Massachusetts startup raised $95.5 million through eight private investment roun... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 13.01.2015 | CoLucid Pharmaceuticals Raises $37.1M in Series C Funding | CoLucid Pharmaceuticals, a Durham, North Carolina-based developer of oral lasmiditan that treats migraine headaches, raised $37.1m in Series C funding.
The round was led by TVM Capital Life Science with participation from Novo Ventures, Aur... |
| 13.01.2015 | CoLucid Pharmaceuticals Inks $37.1M in Series C |
DURHAM, NC, CoLucid Pharmaceuticals, Inc., today announced that it has completed a $37.1 million Series C preferred stock offering.
>> Click here for more funding data on CoLucid Pharmaceuticals
>> To export CoLucid Pharmace... |
| 13.01.2015 | CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C Preferred Stock Offering | |
| 13.01.2015 | CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C Preferred Stock Offering | Durham, NC, January 13, 2015 — CoLucid Pharmaceuticals, Inc., today announced that it has completed a $37.1 million Series C preferred stock offering. The financing was led by TVM Capital Life Science, based in Montreal and Munich, and incl... |
| 16.05.2014 | Lilly Endowment takes stock of year with $270.3M in grants | - |
| 11.11.2012 | Soldiers-turned-CEOs: 5 healthcare companies with U.S. military veterans in the top seat | What do Johnson & Johnson, FedEx and Verizon Communications have in common? Aside from being Fortune 500 companies, they’re also led by former members of the U.S. military.
According to a new Kauffman Foundation study just released, vet... |
| 15.02.2012 | Pharmas, medical device makers set to pitch at CED Life Science conference | A total of 16 companies are scheduled to make presentations, split evenly between pharmaceuticals and medical devices. Here’s a quick rundown of the presenting companies, all of whom are either based in North Carolina’s Research Triangle or... |
| 30.08.2011 | CoLucid raises $7.5M for novel migraine headache drug | Durham, North Carolina-based CoLucid’s lead drug candidate is called lasmiditan. The compound is being developed as a migraine treatment that offers headache relief without the cardiovascular side effects associated with triptans, the class... |
| 30.08.2011 | CoLucid Pharmaceuticals Raises $7.5M | CoLucid Pharmaceuticals, Inc., a Research Triangle Park, NC-based privately held biopharmaceutical company, has raised $7.5m of a planned $9.5m convertible note financing.
Backers include existing investors Pappas Ventures, Domain Associate... |
| 30.08.2011 | CoLucid Pharmaceuticals Raises $7.5M |
Participating in the financing were Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.
>> Click here for more funding data on CoLucid Pharmaceuticals
>> To export CoL... |
| 18.08.2011 | CoLucid in talks with partners for novel migraine treatment | Durham, North Carolina-based CoLucid has raised about $40 million in venture capital from Pappas Ventures, Care Capital, Domain Associates, Pearl Street Venture Funds and Triathlon Medical Ventures. The company was founded in 2005 by Pappas... |
| 15.07.2011 | CNS pharma CoLucid names new CEO; aims for phase 3 trials on migraine drug | Mathers comes to Durham, North Carolina-based CoLucid from Peptimmune, a Massachusetts drug development company that was developing a new multiple sclerosis drug. Peptimmune filed for chapter 7 bankruptcy earlier this year after failing to ... |
| 29.06.2011 | Migraine headache treatment drugmaker CoLucid adds $1.5 million | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 09.03.2011 | NC biotech CoLucid eyes phase 3 trials for novel migraine treatment | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 13.07.2010 | Lilly’s Alzheimer’s gamble takes aim at $10 billion in patent losses | - |
| 10.03.2009 | Pappas Ventures closes $102 million life science fund | “We have long been intrigued by the medical research activity in places like Indiana and Ohio,” said Worthy, who described the states as “underserved areas” along with Texas, Tennessee and Florida.
With this closing, Pappas has $350 million... |
| 24.11.2008 | Lilly closes $6.3B ImClone acquisition | - |
| 28.05.2007 | Orphan Lilly antibiotic spurs $86.3 million IPO plan: Targanta Therapeutics aims to commercialize drug | - |
| - | CoLucid raises $7.5M for novel migraine headache drug | CoLucid Pharmaceuticals has raised $7.5 million of a planned $9.5 million financing to support the central nervous system drug development company’s late-stage development of its novel migraine headache treatment.
Participating in the conve... |
| - | Pappas Ventures closes $102 million life science fund | North Carolina-based Pappas Ventures closed its fourth fund, a $102 million round that will invest in “product-oriented biopharmaceutical companies, with a secondary focus on medical technologies,” according to a news release.
Pappas expect... |
| - | Soldiers-turned-CEOs: 5 healthcare companies with U.S. military veterans in the top seat | What do Johnson & Johnson, FedEx and Verizon Communications have in common? Aside from being Fortune 500 companies, they’re also led by former members of the U.S. military.
According to a new Kauffman Foundation study just released, vet... |
| - | CNS pharma CoLucid names new CEO; aims for phase 3 trials on migraine drug | Central nervous system disorders pharmaceutical company CoLucid has named a new CEO who takes over a firm that is making progress on what is expected to be a breakthrough migraine headache treatment.
Thomas Mathers takes the reins at Durham... |
| - | Migraine headache treatment drugmaker CoLucid adds $1.5 million | Research Triangle Park-based CoLucid Pharmaceuticals raised another $1.5 million recently to bring its latest round of fundraising to $3.5 million, according to a Tuesday filing with the Securities and Exchange Commission.
The drug developm... |
| - | Lilly drops $960M to acquire CoLucid and its late-stage migraine drug | Eli Lilly announced Wednesday that it had acquired CoLucid Pharmaceuticals for $46.50 per share in an all-cash transaction.
That’s around $960 million for a one-trick pony, in the best possible sense of the word.
CoLucid is built around las... |
| - | NC biotech CoLucid eyes phase 3 trials for novel migraine treatment | A new migraine treatment under development by CoLucid Pharmaceuticals is approaching late-stage clinical trials and the Durham, North Carolina-based company is raising $6.5 million in a bridge round of financing to get it there.
Securities ... |
| - | CoLucid in talks with partners for novel migraine treatment | Central nervous system drug development company CoLucid is currently in talks with potential partners who could take its investigational migraine headache treatment into late-stage clinical trials.
The company offered no details on the pros... |
| - | Pharmas, medical device makers set to pitch at CED Life Science conference | Life science companies and investors, let’s make a deal.
The annual CED Life Science Conference kicks off in Raleigh, North Carolina today where small drug developers hope to make the right connection with a big pharmaceutical company or ve... |
